Published in Hepatitis Weekly, April 11th, 2005
The Gilead Access Program makes Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate) available to physicians and treatment programs in countries at the no-profit prices of US$29.75 per month (US$0.99 per day) and US$24.71 per month (US$0.82 per day), respectively.
Gilead's global Access Program was initiated in April 2003 and originally served 68 countries, including every country in Africa and 15 additional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly